With drug discovery being an expensive process and genetic-based drugs being more likely to succeed, the level of investment in omics in drug discovery is increasing. By using genomics in tandem with other omics, drug hunters are increasingly utilising a multi-omics approach to guide and transform their future pipelines.
However, despite technological advancements enabling the collection of new data, the management and interpretation of this data remains very challenging and requires specialised bioinformatic approaches. Is multi-omics in drug discovery the key to new insights or just an expensive bottleneck?
Join us for Omics in Drug Discovery ONLINE, a three-part webinar series, and learn how drug hunters are approaching drug discovery, how molecular data is influencing drug target ID and how pharmaceutical companies are getting past their data challenges. This series will introduce case studies from different disease areas presented by expert speakers from companies such as Pfizer, AstraZeneca, Biogen and Eisai.
By registering for the first webinar in the series you will automatically gain access to the subsequent webinars.
Webinar 1: Utilising Omics Datasets for Drug Target ID and Validation
Thursday, 4th November at 3pm GMT/ 4pm CET/ 11am EDT
It has been shown that drugs associated with a genetic variant double the chances of clinical development success. Since this discovery, pharma companies have been heavily investing in genomic technologies. This webinar will cover how genetics and genomics are influencing drug discovery and development in tandem with other datasets.
- Talk 1: Human Genetics and Multi-Omics Approach to Identification and Validation of Novel Therapeutic Targets
- Morten Sogaard, VP, Target Sciences, Pfizer
- Talk 2: Designing for Success – Multi-Omics Experiments to Support Drug Discovery
- Natalie van Zuydam, Senior Statistician in Data Science and Quantitative Biology, AstraZeneca
- Talk 3: Chronic disease through the lens of aging: target discovery using multi-omic profiling of longitudinal healthy aging cohorts
- Eric Morgen, Co-founder and COO, and Naisha Shah, Director of Data Science, Bioage Labs
Webinar 2: Multi-omics Approaches to Drug Discovery
Thursday, 11th November at 3pm GMT/ 4pm CET/ 10am EST
This webinar will focus on collecting and leveraging deep phenotypic data within the drug discovery process, and addressing the challenges associated with analysing, integrating and interpreting that data.
- Talk 1: Accelerating Genetics-guided Drug Discovery by Integrating Population-scale Proteomics
- Christopher Whelan, Associate Director and Head of Translational Genetics, Biogen
- Talk 2: Unfolding New Disease Biology, Targets and Pathways Using Omicsfold
- Shameer Khader, Senior Director, AstraZeneca
- Talk 3: Addressing Biology with Novel Spatial-Omics Technologies
- Jessica Runyon, Head of Product Management, Canopy Biosciences
Webinar 3: Biomarkers, Diagnostics, and Personalised Medicine
Thursday, 18th November at 3pm GMT/ 4pm CET/ 10am EST
Discovering and developing drugs is an expensive process. To ensure the likelihood of best results, utilising molecular technologies is pivotal to enable the next era of personalised medicine. This webinar will focus on how omics are influencing the discovery of novel biomarkers and the development of targeted therapies and companion diagnostics to develop better and more effective drugs.
- Talk 1: Single-cell DNA Sequencing to Discover Novel Drugs Targets in Leukaemia
- Jan Cools, Professor, KU Leuven
- Talk 2: Applying Alzheimer’s Disease Genetics Findings Towards Drug Discovery and Patient Selection
- Michael Nagle, Senior Director, Head of Neurogenomics, Eisai US
This webinar series has been made possible due to the kind support of our partners 10x Genomics, Bioage Labs and Canopy Biosciences.
Register for the webinar series:
